LMY-920 for Treatment of Relapsed or Refractory Myeloma

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Luminary Therapeutics
Study ID
NCT05546723
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Autologous CAR-T cell therapy expressing the BAFF-ligand. — BIOLOGICAL
    LMY-920

Study Details

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.

Key Dates

Start date
Mar 13, 2024
Status verified
Oct 2024
Primary completion
Jul 31, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: LMY-920 dose escalation
    Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.

Primary Outcome Measure

To determine recommended phase II dose of human LMY-920 in patients with relapsed or refractory myeloma. [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University Hospitals Seidman Cancer CenterClevelandOhio44106
Leland Metheny, MD
[email protected]
2168440139

Find similar trials in Cleveland, OH

By research site
University Hospitals Seidman Cancer Center· Cleveland, OH

Related Studies